Advances in Hematology / 2017 / Article / Tab 1

Review Article

The Evolution of Prognostic Factors in Multiple Myeloma

Table 1

Various risk stratification models.

Risk stratification modelPrognostic markersOSReference

mSMART(i) Cytogenetics(i) Low risk: 10 years [36]
(ii) GEP(ii) Intermediate risk: 4.5 years
(iii) PCLI(iii) High risk: 3 years

IMWG(i) ISS  
(ii) Cytogenetics
(i) Low risk: >10 years [37]
(ii) Standard risk: 7 years
(iii) High risk: 2 years

IFM(i) LDHScore 0–3. Score 3 had very poor prognosis [38]
(ii) ISS
(iii) Cytogenetics